A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Recruiting now · Phase 1/Phase 2

Conditions studied: ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer

In brief

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: * Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing * Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter * Keep a diary of each time they take the study medication

Key facts

Study ID

NCT07491497

Run by

TRIANA Biomedicines, Inc.

People needed

160

Starts

2026-03-11

Expected to finish

2034-01-30

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed diagnosis of ALK-positive non-small cell lung cancer (NSCLC)
• Measurable disease per RECIST v1.1
• Adequate bone marrow reserve and organ function
• Part 1: prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line
• Part 2 Cohort M1: prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line, prior treatment with neladalkib is excluded
• Part 2 Cohort M2: prior treatment with more than 3 ALK TKIs, prior treatment with lorlatinib and neladalkib is required but neither may have been in the first line
• Part 2 Cohort M3: participants without prior ALK TKI treatment

You may not qualify if…

• Participant's cancer has any additional driver alterations known to be a mechanism of resistance to ALK TKIs
• For participants with central nervous system (CNS) metastases or spinal cord compression, they must not be associated with progressive neurological symptoms or require increasing doses of corticosteroids to control the CNS disease
• Ongoing treatment with another anticancer treatment or investigational agent
• Known allergy/hypersensitivity to TRI-611 or any of its ingredients
• Major surgery within 4 weeks of receiving the first dose of TRI-611

Where it is running

• UCSF — San Francisco, California, United States (enrolling)
• University of Colorado Cancer Center — Aurora, Colorado, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Dana Farber Cancer Center — Boston, Massachusetts, United States (enrolling)
• Washington University Medical Center — St Louis, Missouri, United States (enrolling)
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States (enrolling)
• Duke University — Durham, North Carolina, United States (enrolling)
• Taylor Cancer Research Center — Maumee, Ohio, United States (enrolling)
• SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
• Oncology Consultants Research (P1 Trials) — Houston, Texas, United States (enrolling)
• START Mountain Region — West Valley City, Utah, United States (enrolling)
• NEXT Virginia — Fairfax, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.